This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by FINNERTY, F. A. Articles by FREIS, E. D. Search for Related Content PubMed PubMed Citation Articles by FINNERTY, F. A., JR. Articles by FREIS, E. D.

(Circulation. 1950;2:828.)
© 1950 American Heart Association, Inc.

---

Experimental and Clinical Evaluation in Man of Hexamethonium (C6), A New Ganglionic Blocking Agent

FRANK A. FINNERTY JR. M.D.¹ EDWARD D. FREIS M.D.¹

¹ From the Department of Medicine, Georgetown University Hospital and Georgetown University School of Medicine, and the Veterans Administration Hospital, Washington, D. C.

In man, C6, a new ganglionic blocking agent (50 mg. intravenously) produced inhibition of the Valsalva, tiltback and cold pressor vasopressor responses. Marked increases in digital blood flow and skin temperature with inhibition of digital reflexes to "noxious" stimuli were consistently observed (room temperature 70 F.). The increase in skin temperature was greater and more lasting than following Priscoline or tetraethylammonium chloride. Except for severe postural hypotension, side effects were minimal. Clinically the drug may be useful in the evaluation of sympathetic vasoconstriction in peripheral vascular disease as well as in the treatment of acute neurogenic vasospasm.

This article has been cited by other articles:

				E. D. FREIS and I. M. WILSON Mecamylamine, a New, Orally Effective, Experimental and Clinical Evaluation Arch Intern Med, May 1, 1956; 97(5): 551 - 561. [Abstract] [PDF]